Merck's Keytruda achieves 24 percent response in bladder cancer study

(Reuters) - Merck & Co's immunotherapy Keytruda proved effective as an initial treatment for nearly a quarter of patients with advanced bladder cancer too frail for standard cisplatin chemotherapy, according to interim results from a study presented on Saturday.